Gilead Sciences
Gilead Sciences is committed to creating a healthier world for all people by discovering, developing, and delivering innovative therapeutics for life-threatening diseases. The company focuses on therapeutic areas such as virology, oncology, and inflammation, and invests in world-class science and innovation. Gilead also emphasizes corporate responsibility, health equity, and community partnerships to break down barriers to care.
Industries
Nr. of Employees
Very Large (1000+)
Gilead Sciences
Patents
Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)
US-12297282-B2
View Details
Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)
US-12297282-B2
View DetailsProducts
Portfolio of marketed therapeutics
A portfolio of marketed medicines across virology, oncology and inflammation for global distribution.
Clinical development pipeline (investigational programs)
Active clinical pipeline with multiple clinical programs across virology, oncology and inflammation.
BIKTARVY
Biktarvy is a fixed-dose combination tablet containing bictegravir, emtricitabine, and tenofovir alafenamide for HIV treatment.
BIKTARVY® 50/200/25 mg
Bictegravir as sodium 50 mg, emtricitabine 200 mg, tenofovir alafenamide as fumarate 25 mg fixed-dose combination tablet.
BIKTARVY® 30/120/15 mg
Bictegravir as sodium 30 mg, emtricitabine 120 mg, tenofovir alafenamide as fumarate 15 mg fixed-dose combination tablet.
Atripla
Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg. Complete regimen for the treatment of HIV-1 infection.
Portfolio of marketed therapeutics
A portfolio of marketed medicines across virology, oncology and inflammation for global distribution.
Clinical development pipeline (investigational programs)
Active clinical pipeline with multiple clinical programs across virology, oncology and inflammation.
BIKTARVY
Biktarvy is a fixed-dose combination tablet containing bictegravir, emtricitabine, and tenofovir alafenamide for HIV treatment.
BIKTARVY® 50/200/25 mg
Bictegravir as sodium 50 mg, emtricitabine 200 mg, tenofovir alafenamide as fumarate 25 mg fixed-dose combination tablet.
BIKTARVY® 30/120/15 mg
Bictegravir as sodium 30 mg, emtricitabine 120 mg, tenofovir alafenamide as fumarate 15 mg fixed-dose combination tablet.
Atripla
Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg. Complete regimen for the treatment of HIV-1 infection.
Services
Design and execution of clinical development plans and management of worldwide clinical trials.
CMC activities including process chemistry, formulation, analytical development, device and sterile process engineering and supply for clinical studies.
Administration of external grant programs, RFP opportunities and sponsored-research partnerships across virology, oncology and inflammation.
Provision of medical information resources and adverse event reporting mechanisms.
Design and execution of clinical development plans and management of worldwide clinical trials.
CMC activities including process chemistry, formulation, analytical development, device and sterile process engineering and supply for clinical studies.
Administration of external grant programs, RFP opportunities and sponsored-research partnerships across virology, oncology and inflammation.
Provision of medical information resources and adverse event reporting mechanisms.
Expertise Areas
- Virology research and drug development
- Oncology research and therapeutics
- Inflammation and immunology research
- Clinical trial management and operations
Key Technologies
- Cryo-electron microscopy
- Structure-based drug design
- Protein engineering
- Biologics discovery platforms
News & Updates
#1 Funder of HIV Programs in the U.S.
Gilead is the leading funder of HIV programs in the United States.
#1 Funder of HIV Programs in the U.S.
Gilead is the leading funder of HIV programs in the United States.